Phenylacetohydroxamic Acid

Phenylacetohydroxamic Acid

SCHEMBL213873

O=C(Cc1ccccc1)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 6/20 1.00
HDAC6 Q9UBN7 5/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
HDAC2 Q92769 4/20 0.63
EPHX2 P34913 1/20 0.63
HDAC1 Q13547 5/20 0.59
HDAC3 O15379 3/20 0.59
HDAC5 Q9UQL6 3/20 0.59
HDAC4 P56524 2/20 0.59
HDAC7 Q8WUI4 2/20 0.59
HDAC10 Q969S8 2/20 0.59
HDAC11 Q96DB2 2/20 0.59
HDAC9 Q9UKV0 2/20 0.59
CES2 O00748 1/20 0.58
CES1 P23141 1/20 0.58
AKR1B1 P15121 1/20 0.58
ALDH1A1 P00352 1/20 0.57
CNR2 P34972 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylacetohydroxamic Acid SCHEMBL8893714 0.98 HDAC8 (0.95) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL4581295 0.88 HDAC8 (0.78) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL4580449 0.88 HDAC8 (0.78) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL8664637 0.87 KMT2A (0.77) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL16050194 0.87 HDAC8 (0.75) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL4579041 0.87 HDAC8 (0.75) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL16050112 0.87 HDAC8 (0.75) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL14811482 0.87 HDAC8 (0.79) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL10447485 0.85 HDAC8 (0.73) HDAC8HDAC6MEN1KMT2AHDAC2
SCHEMBL4821967 0.84 MEN1 (0.72) HDAC8HDAC6MEN1KMT2AHDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634703-B1 PROCESS FOR SUPERCRITICAL OR SUBCRITICAL PARTIAL DELIGNIFICATION AND FILLING OF A LIGNOCELLULOSIC MATERIAL SAS WOODOO (FR) 2025-04-23 EP claimed
US-11820041-B2 Process for supercritical or subcritical partial delignification and filling of a lignocellulosic material SAS WOODOO (FR) 2023-11-21 US claimed
US-20200164542-A1 PROCESS FOR SUPERCRITICAL OR SUBCRITICAL PARTIAL DELIGNIFICATION AND FILLING OF A LIGNOCELLULOSIC MATERIAL SAS WOODOO (FR) 2020-05-28 US claimed
CN-106916073-A A kind of synthetic method of hordenine hydrochloride 上海巧坤化工科技有限公司 2017-07-04 CN claimed
US-20150038330-A1 Chemical Compositions and Methodology to Enhance Plant Growth and Development MCDANIEL ROBERT GENE (US) 2015-02-05 US claimed
EP-2227233-A2 IDO INHIBITORS Newlink Genetics (US) 2010-09-15 EP claimed
WO-2009073620-A2 IDO INHIBITORS NEWLINK GENETICS (US) 2009-06-11 WO claimed
EP-1948164-A1 PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES, LTD. (IN) 2008-07-30 EP claimed
EP-1888525-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-02-20 EP claimed
EP-1797040-A1 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-20 EP claimed
WO-2007045979-A1 PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-04-26 WO claimed
WO-2006117754-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO claimed
WO-2006035303-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-04-06 WO claimed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US claimed
EP-1362511-A1 Protective solution for preventing ischaemia Dr. Franz Köhler Chemie GmbH (DE) 2003-11-19 EP claimed
EP-1265855-A1 NOVEL CD23 INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2002-12-18 EP claimed
WO-2001062715-A1 NOVEL CD23 INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2001-08-30 WO claimed
JP-55062050-A None JP disclosed
US-4092430-A ANTICOAGULANTS, ANALGESTIC, ANTIPYRETIC ACTIVITY CIBA-GEIGY CORPORATION (US) 1978-05-30 US disclosed
US-4092430-A ANTICOAGULANTS, ANALGESTIC, ANTIPYRETIC ACTIVITY CIBA-GEIGY CORPORATION (US) 1978-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030215781-A1 Protective solutions for organs GLS, CA1, SI HDAC8 95/4885HDAC6 365/4885MEN1 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.